Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Assets (2022 - 2025)

Historic Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $240.3 million.

  • Phathom Pharmaceuticals' Assets fell 3791.69% to $240.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.3 million, marking a year-over-year decrease of 3791.69%. This contributed to the annual value of $378.3 million for FY2024, which is 858.4% down from last year.
  • Phathom Pharmaceuticals' Assets amounted to $240.3 million in Q3 2025, which was down 3791.69% from $250.2 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Assets high stood at $413.8 million for Q4 2023, and its period low was $144.0 million during Q1 2023.
  • Moreover, its 4-year median value for Assets was $250.2 million (2025), whereas its average is $267.7 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 15110.25% in 2023, then crashed by 3791.69% in 2025.
  • Phathom Pharmaceuticals' Assets (Quarter) stood at $164.8 million in 2022, then surged by 151.1% to $413.8 million in 2023, then dropped by 8.58% to $378.3 million in 2024, then crashed by 36.48% to $240.3 million in 2025.
  • Its Assets was $240.3 million in Q3 2025, compared to $250.2 million in Q2 2025 and $294.2 million in Q1 2025.